Intellia Therapeutics Inc (NASDAQ: NTLA) open the trading on Thursday, with a bit cautious approach as it glided -0.84% to $21.32, before settling in for the price of $21.50 at the close. Taking a more long-term approach, NTLA posted a 52-week range of $21.44-$47.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 12.09% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -22.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -2.45%. This publicly-traded company’s shares outstanding now amounts to $96.11 million, simultaneously with a float of $93.89 million. The organization now has a market capitalization sitting at $2.05 billion. At the time of writing, stock’s 50-day Moving Average stood at $27.31, while the 200-day Moving Average is $31.24.
Intellia Therapeutics Inc (NTLA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Intellia Therapeutics Inc’s current insider ownership accounts for 2.30%, in contrast to 85.59% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’24, this organization’s EVP, General Counsel sold 2,297 shares at the rate of 32.99, making the entire transaction reach 75,778 in total value, affecting insider ownership by 81,571. Preceding that transaction, on Mar 04 ’24, Company’s EVP, Chief Technical Officer sold 605 for 32.99, making the whole transaction’s value amount to 19,959. This particular insider is now the holder of 71,470 in total.
Intellia Therapeutics Inc (NTLA) Earnings and Revenue Records
Intellia Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -2.45% and is forecasted to reach -5.64 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 30.00% through the next 5 years, which can be compared against the -22.30% growth it accomplished over the previous five years trading on the market.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Let’s observe the current performance indicators for Intellia Therapeutics Inc (NTLA). It’s Quick Ratio in the last reported quarter now stands at 8.67. The Stock has managed to achieve an average true range (ATR) of 1.25. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 56.49.
In the same vein, NTLA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.42, a figure that is expected to reach -1.38 in the next quarter, and analysts are predicting that it will be -5.64 at the market close of one year from today.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
[Intellia Therapeutics Inc, NTLA] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 1.41% While, its Average True Range was 1.14.
Raw Stochastic average of Intellia Therapeutics Inc (NTLA) in the period of the previous 100 days is set at 1.02%, which indicates a major fall in contrast to 2.23% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 45.74% that was lower than 58.78% volatility it exhibited in the past 100-days period.
